<DOC>
	<DOCNO>NCT01930864</DOCNO>
	<brief_summary>MetIri seek identify metformin combine irinotecan improve tumor control .</brief_summary>
	<brief_title>Metformin Plus Irinotecan Refractory Colorectal Cancer</brief_title>
	<detailed_description>MetIri two-stage single arm Phase II assess role combination metformin irinotecan colorectal cancer patient already treat oxaliplatin , fluoropyrimidine , irinotecan anti-EGFr antibody Kras wild type .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>18 year old Biopsyproven colorectal adenocarcinoma Ineligibility curative intent therapy , e.g. , surgery radiation Disease progression oxaliplatin ( either adjuvant palliative ) , fluoropyrimidine ( either adjuvant palliative ) , irinotecan , Kras wild type antiEGFR therapy Assessable disease accord RECIST v1.1 know hypersensitivity metformin irinotecan CNS metastasis Acute chronic severe infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>metformin</keyword>
	<keyword>colorectal cancer</keyword>
	<keyword>chemotherapy</keyword>
</DOC>